Skip to main navigation Skip to search Skip to main content

Genome-wide polygenic risk scores for colorectal cancer have implications for risk-based screening

  • Max Tamlander
  • , Bradley Jermy
  • , Toni T. Seppälä
  • , Martti Färkkilä
  • , FinnGen
  • , Elisabeth Widén
  • , Samuli Ripatti
  • , Nina Mars*
  • *Corresponding author for this work

Research output: Contribution to journal › Article › Scientific › peer-review

18 Citations (Scopus)
46 Downloads (Pure)

Abstract

Background: Hereditary factors, including single genetic variants and family history, can be used for targeting colorectal cancer (CRC) screening, but limited data exist on the impact of polygenic risk scores (PRS) on risk-based CRC screening. Methods: Using longitudinal health and genomics data on 453,733 Finnish individuals including 8801 CRC cases, we estimated the impact of a genome-wide CRC PRS on CRC screening initiation age through population-calibrated incidence estimation over the life course in men and women. Results: Compared to the cumulative incidence of CRC at age 60 in Finland (the current age for starting screening in Finland), a comparable cumulative incidence was reached 5 and 11 years earlier in persons with high PRS (80–99% and >99%, respectively), while those with a low PRS (< 20%) reached comparable incidence 7 years later. The PRS was associated with increased risk of post-colonoscopy CRC after negative colonoscopy (hazard ratio 1.76 per PRS SD, 95% CI 1.54–2.01). Moreover, the PRS predicted colorectal adenoma incidence and improved incident CRC risk prediction over non-genetic risk factors. Conclusions: Our findings demonstrate that a CRC PRS can be used for risk stratification of CRC, with further research needed to optimally integrate the PRS into risk-based screening.

Original languageEnglish
Pages (from-to)651–659
Number of pages9
JournalBritish Journal of Cancer
Volume130
DOIs
Publication statusPublished - 2024
Publication typeA1 Journal article-refereed

Funding

This work was supported by the Sigrid Jusélius Foundation (to SR) Academy of Finland Center of Excellence in Complex Disease Genetics (grant number 312062 to SR); Academy of Finland (grant number 331671 to NM, grant number 285380 to SR); The Finnish Innovation Fund Tekes (grant number 2273/31/2017 to EW); University of Helsinki HiLIFE Fellows Grant 2023-2025 to NM; The European Union’s Horizon 2020 research and innovation programme under grant agreement No 101016775; Finska Läkaresällskapet to NM; The Doctoral Programme in Population Health, University of Helsinki, to MT; TTS is supported by the Cancer Foundation Finland, Jane and Aatos Erkko Foundation, Relander Foundation, Sigrid Jusélius Foundation, Academy of Finland, iCAN Precision Medicine Flagship of the Academy of Finland and the state research funding of Helsinki and Uusimaa hospital district (HUS). Open Access funding provided by University of Helsinki (including Helsinki University Central Hospital).

FundersFunder number
Finnish Innovation Fund Tekes2273/31/2017
Univ Helsinki, University of Helsinki, Inst Mol Med Finland FIMM, HiLIFE2023-2025
Helsingin yliopisto
Finska läkaresällskapet
Horizon 2020 Framework Programme101016775
Academy of Finland331671, 285380
Jane ja Aatos Erkon Säätiö
Sigrid Juséliuksen Säätiö312062
Syöpäsäätiö
Relander Foundation

    UN SDGs

    This output contributes to the following UN Sustainable Development Goals (SDGs)

    1. SDG 3 - Good Health and Well-being
      SDG 3 Good Health and Well-being

    Publication forum classification

    • Publication forum level 2

    ASJC Scopus subject areas

    • Oncology
    • Cancer Research

    Fingerprint

    Dive into the research topics of 'Genome-wide polygenic risk scores for colorectal cancer have implications for risk-based screening'. Together they form a unique fingerprint.

    Cite this